Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
February, 2026
February 2026
M T W T F S S
 1
2345678
9101112131415
16171819202122
232425262728  
James Harte on Asundexian and Milvexian’s Strong, Dose-dependent Interferences in Coagulation Assays
James Harte/LinkedIn
Aug 20, 2025, 05:48

James Harte on Asundexian and Milvexian’s Strong, Dose-dependent Interferences in Coagulation Assays

James Harte, Assistant Lecturer/PhD Candidate on the School of Biochemistry and Cell Biology at University College Cork, proudly reposted from JTH Journal on LinkedIn:

”Delighted to see our work on the laboratory testing of asundexian, milvexian, from the EOLAS Research Group, shared by the Journal of Thrombosis and Haemostasis (JTH).”

JTH Journal shared on LinkedIn:

”Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents.

This study shows that the emerging FXIa inhibitors asundexian and milvexian produce strong, dose-dependent interferences in coagulation assays — potentially leading to misinterpretation of hemostatic function.

Importantly, activated charcoal–based adsorbents (including DOAC-Stop) effectively removed these interferences, enabling accurate coagulation testing in treated plasma.”

Read the full paper here.

Article: Interferences associated with the factor XIa inhibitors asundexian and milvexian in routine and specialized coagulation assays and their removal by activated charcoal-based adsorbents

Authors: Gavin Buckley, Maeve Crowley, James Harte

James Harte on Asundexian and Milvexian's Strong, Dose-dependent Interferences in Coagulation Assays

Stay updated on all science in the field of coagulation disorders with Hemostasis Today.

asundexian Coagulation Assays DOAC-Stop EOLAS Research Group factor XIa inhibitors Gavin Buckley Health Hematology Hemostasis Today James Harte jth Journal Maeve Crowley Medicine milvexian
NewsFeed